10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.

PURPOSE To report outcomes for 1,111 men treated with iodine-125 brachytherapy (BT) at a single institution. METHODS AND MATERIALS A total of 1,111 men (median age, 63) were treated with iodine-125 prostate BT for low- or intermediate-risk prostate cancer between March 1999 and November 2008. Median prostate-specific antigen (PSA) level was 5.4 ng/ml (range, 0.9-26.1). T stage was T1c in 66% and T2 in 34% of patients. Gleason score was 6 in 90.1% and 7 or 8 in 9.9% of patients. Neoadjuvant hormonal therapy (2-6 months course) was used in 10.1% of patients and combined external radiotherapy (45 Gy) with BT (110 Gy) in 4.1% (n = 46) of patients. Univariate and multivariate Cox proportional hazards were used to determine predictors of failure. RESULTS Median follow-up was 42 months (range, 6-114), but for biochemical freedom from relapse, a minimum PSA test follow-up of 30 months was required (median 54; n = 776). There were 27 failures, yielding an actuarial 7-year disease-free survival rate of 95.2% (96 at risk beyond 84 months). All failures underwent repeat 12-core transrectal ultrasound -guided biopsies, confirming 8 local failures. On multivariate analysis, Gleason score was the only independent predictor of failure (p = 0.001; hazard ratio, 4.8 (1.9-12.4). Median International Prostate Symptom score from 12 to 108 months ranged between 3 and 9. Of the men reporting baseline potency, 82.8% retained satisfactory erectile function beyond 5 years. CONCLUSION Iodine-125 prostate BT is a highly effective treatment option for favorable- and intermediate-risk prostate cancer and is associated with maintenance of good urinary and erectile functions.

[1]  Yoshiya Yamada,et al.  Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.

[2]  R. Stock,et al.  Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[3]  R. Stock,et al.  Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[4]  Ivan Yeung,et al.  Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. , 2002, Brachytherapy.

[5]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.

[6]  G. Perry,et al.  Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. , 2000, International journal of radiation oncology, biology, physics.

[7]  W. Butler,et al.  Erectile function after permanent prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[8]  G. Pond,et al.  Long-term urinary sequelae following 125iodine prostate brachytherapy. , 2008, The Journal of urology.

[9]  W. J. Morris,et al.  Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. , 2010, International journal of radiation oncology, biology, physics.

[10]  W. J. Morris,et al.  Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. , 2009, Urology.

[11]  J. Crook,et al.  Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Bristow,et al.  A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  M. Kattan,et al.  Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. , 2010, International journal of radiation oncology, biology, physics.

[14]  R. Stock,et al.  Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function , 2006, BJU international.

[15]  J. Ciezki,et al.  Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[16]  G. Pond,et al.  Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. , 2006, Brachytherapy.

[17]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[18]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[19]  R. Stock,et al.  Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. , 2010, The Journal of urology.

[20]  Jose A Gonzalez,et al.  No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. , 2003, The Journal of urology.

[21]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Unger,et al.  Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. , 2008, International journal of radiation oncology, biology, physics.

[23]  P. Carroll,et al.  What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. , 2007, The Journal of urology.

[24]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[25]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[26]  C. Ménard,et al.  Image guided dose escalated prostate radiotherapy: still room to improve , 2009, Radiation oncology.

[27]  D. Beyer,et al.  Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[28]  N. Mabjeesh,et al.  Sexual function after permanent 125I-brachytherapy for prostate cancer , 2005, International Journal of Impotence Research.

[29]  N. Mabjeesh,et al.  Sexual function after permanent 125 I-brachytherapy for prostate cancer , 2004 .

[30]  L. Potters,et al.  Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. , 2005, Brachytherapy.

[31]  Blasko,et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International Journal of Radiation Oncology, Biology, Physics.

[32]  Robert W Galbreath,et al.  15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. , 2007, International journal of radiation oncology, biology, physics.

[33]  L. Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.

[34]  M. Johnston,et al.  Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[35]  M. Mclean,et al.  Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[36]  G. Lockwood,et al.  PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.

[37]  J. Cappelleri,et al.  Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction , 1999, International Journal of Impotence Research.

[38]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.